Adegramotide

Adegramotide

Legal status
Legal status	experimental
Identifiers
IUPAC name L-tryptophyl-L-alanyl-L-prolyl-L-valyl-L-leucyl-L-alpha-aspartyl-L-phenylalanyl-L-alanyl-L-prolyl-L-prolyl-glycyl-L-alanyl-L-seryl-L-alanyl-L-tyrosyl-glycyl-L-seryl-L-leucine
CAS Number	1252802-98-4
PubChem CID	121488164
ChemSpider	59651405
UNII	4XQ7W02EQ0
KEGG	D11057
CompTox Dashboard (EPA)	DTXSID701337273
Chemical and physical data
Formula	C87H123N19O24
Molar mass	1819.050 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCCN3C(=O)[C@H](C)NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](C)NC(=O)[C@H](CC6=CNC7=CC=CC=C76)N
InChI InChI=InChI=1S/C87H123N19O24/c1-44(2)33-58(100-83(125)71(46(5)6)103-82(124)66-24-17-30-104(66)84(126)49(9)94-74(116)56(88)37-53-39-89-57-22-15-14-21-55(53)57)77(119)99-61(38-70(112)113)78(120)98-60(35-51-19-12-11-13-20-51)76(118)95-50(10)85(127)106-32-18-25-67(106)86(128)105-31-16-23-65(105)81(123)91-40-68(110)92-47(7)72(114)102-64(43-108)79(121)93-48(8)73(115)97-59(36-52-26-28-54(109)29-27-52)75(117)90-41-69(111)96-63(42-107)80(122)101-62(87(129)130)34-45(3)4/h11-15,19-22,26-29,39,44-50,56,58-67,71,89,107-109H,16-18,23-25,30-38,40-43,88H2,1-10H3,(H,90,117)(H,91,123)(H,92,110)(H,93,121)(H,94,116)(H,95,118)(H,96,111)(H,97,115)(H,98,120)(H,99,119)(H,100,125)(H,101,122)(H,102,114)(H,103,124)(H,112,113)(H,129,130)/t47-,48-,49-,50-,56-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,71-/m0/s1 Key:QMUKFZMAYHSADK-MZDDNWLQSA-N

Adegramotide (DSP-7888) is an experimental drug intended for treatment of various hematologic malignancies and solid tumors, including glioblastoma multiforme. ^[1] It is a peptide vaccine and has finished phase I clinical trials and phase II clinical trials. ^{[2] [3]}

As of 14 December 2021, phase III clinical research has been cancelled due to low efficacy markers during interim review of study data for Ombipepimut-S Emulsion (DSP-7888) in combination with Bevacizumab. ^{[4] [5]}

The phase III trials for DSP-7888 with checkpoint inhibitors for platinum-resistant ovarian cancer, as of 13 August 2024, is still continuing as planned. ^{[4] [6]}

References

1. Spira A, Hansen AR, Harb WA, Curtis KK, Koga-Yamakawa E, Origuchi M, Li Z, Ertik B, Shaib WL (July 2021). "Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies". Targeted Oncology. 16 (4): 461–469. doi:10.1007/s11523-021-00813-6. PMC   8266707 . PMID   33939067.
2. Boston Biomedical (11 May 2017). "A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy". ClinicalTrials.gov. U.S. National Library of Medicine.
3. Suginobe; et al. "Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors". pubchem.ncbi.nlm.nih.gov.
4. Sumitomo Dainippon Pharma Oncology Inc. "Sumitomo Dainippon Pharma Oncology Provides Update on Phase 3 WIZARD 201G Study of Ombipepimut-S Emulsion (DSP-7888) in Patients with Recurrent or Progressive Glioblastoma". www.prnewswire.com. Archived from the original on 2024-08-13. Retrieved 2024-08-13.
5. "Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888 in Patients with Glioblastoma Terminates | Sumitomo Pharma". www.sumitomo-pharma.com. Archived from the original on 2024-08-13. Retrieved 2024-08-13.
6. "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors". clinicaltrials.gov. Archived from the original on 2024-08-13. Retrieved 2024-08-13.